2016

150.00 rub.
Buy article
2016/№6

Controversial questions of pharmacotherapy of chronic heart failure (Review). Part 1. Kind/evil magician digoxin

Lyasnikova E.A., Sitnikova M.Yu.
Federal State Budgetary Institution "Federal Almazov North-West Medical Research Center" of the Ministry of Health of the Russian Federation, Akkuratova 2, St. Petersburg 197341

Keywords: digoxin, heart failure

DOI: 10.18087/rhfj.2016.6.2291

This is a review of controlled clinical studies and meta-analyses of studies on digoxin efficacy and safety in different forms of heart failure and atrial fibrillation.
  1. Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation. 2006 May 30;113 (21): 2556–64.
  2. Ambrosy AP, Butler J, Ahmed A, Vaduganathan M, van Veldhuisen DJ, Colucci WS, Cheorghiade M. The use of digoxin in patients with worsening chronic heart failure. J Am Coll Cardiol. 2014 May 13;63 (18):1823–32.
  3. Opie LH. Digitalis, yesterday and today, but not forever. Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6 (5):511–13.
  4. Wang L, Wible BA, Wan X, Ficker E. Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. J Pharmacol Exp Ther. 2007 Feb;320 (2):525–34.
  5. Gheorghiade M, Adams KF, Colucci WS. Digoxin in the management of cardiovascular disorders. Circulation. 2004 Jun 22;109 (24):2959–64.
  6. Rathore SS, Curtis JP, Wang Y, Bristow MR , Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003 Feb 19;289 (7):871–8.
  7. Fauchier L, Grimard C, Pierre B, Nonin E, Gorin L, Rauzy B et al. Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Am J Cardiol. 2009 Jan 15;103 (2):248–54.
  8. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37 (27):2129–200.
  9. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62 (16): e147–239.
  10. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014 Dec 2;130 (23):e199–267.
  11. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31 (19):2369–429.
  12. Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П., Коротеев А.В., Мареев Ю.В., Овчинников А.Г. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Утверждены на Конгрессе ОССН 7 декабря 2012 года, на Правлении ОССН 31 марта 2013 и Конгрессе РКО 25 сентября 2013 года. Журнал Сердечная Недостаточность. 2013;14 (7):379–472 [Mareev V.Yu., Ageev F.T., Arutyunov G.P., Koroteev A.V., Mareev Yu.V., Ovchinnikov A.G. i dr. Naczional`ny`e rekomendaczii OSSN, RKO i RNMOT po diagnostike i lecheniyu XSN (chetverty`j peresmotr). Utverzhdeny` na Kongresse OSSN 7 dekabrya 2012 goda, na Pravlenii OSSN 31 marta 2013 i Kongresse RKO 25 sentyabrya 2013 goda. Zhurnal Serdechnaya Nedostatochnost`. 2013;14 (7):379–472].
  13. Сулимов В.А., Голицын С.П., Панченко Е.П., Попов С.В., Ревишвили А.Ш., Шубик Ю.В. и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА и АССХ. Российский кардиологический журнал. 2013;4 S3 (102):1–100 [Sulimov V.A., Goliczy`n S. P., Panchenko E.P., Popov S.V., Revishvili A.Sh., Shubik Yu.V. i dr. Diagnostika i lechenie fibrillyaczii predserdij. Rekomendaczii RKO, VNOA i ASSX. Rossijskij kardiologicheskij zhurnal. 2013;4 S3 (102):1–100].
  14. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin with-drawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol. 1993 Oct;22 (4):955–62.
  15. Packer M, Gheorghiade M, Young JB, Costantini PJ, Adams KF, Cody RJ et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med. 1993 Jul 1;329 (1):1–7.
  16. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997 Feb 20;336 (8):525–33.
  17. Gheorghiade M, Patel K, Filippatos G, Anker SD, van Veldhuisen DJ, Cleland JG et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013 May;15 (5):551–9.
  18. Ahmed A, Rich MW, Fleg JL, Zile MR , Young JB, Kitzman DW et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006 Aug 1;114 (5):397–403.
  19. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002 Oct 31;347 (18):1403–11.
  20. Adams KF, Patterson JH, Gattis WA, O'Connor CM, Lee CR, Schwartz TA, Gheoghiade M. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005 Aug 2;46 (3):497–504.
  21. See I, Shehab N, Kegler SR , Laskar SR , Budnitz DS. Emergency department visits and hospitalizations for digoxin toxicity: United States, 2005 to 2010. Circ Heart Fail. 2014 Jan;7 (1):28–34.
  22. Rich MW, McSherry F, Williford WO, Yusuf S. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol. 2001 Sep;38 (3):806–13.
  23. Testani JM, Brisco MA, Tang WH, Kimmel SE, Tiku-Owens A, Forfia PR , Coca SG. Potential effects of digoxin on long-term renal and clinical outcomes in chronic heart failure. J Card Fail. 2013 May;19 (5):295–302.
  24. Castagno D, Petrie MC, Claggett B, McMurray JJ. Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J. 2012 May;33 (9):1137–41.
  25. Butler J, Anand IS, Kuskowski MA, Rector T, Carson P, Cohn JN. Digoxin use and heart failure outcomes: results from the valsartan heart failure trial (Val-HeFT). Congest Heart Fail. 2010 Sep-Oct;16 (5):191–5.
  26. Georgiopoulou VV, Kalogeropoulos AP, Giamouzis G, Agha SA, Rashad MA, Waheed S et al. Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy. Circ Heart Fail. 2009 Mar;2 (2):90–7.
  27. Freeman JV, Yang J, Sung SH, Hlatky MA, Go AS. Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure. Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6 (5):525–33.
  28. Hood WB, Dans AL, Guyatt GH, Jaeschke R , McMurray JJ. Digitalis for treatment of heart failure in patients in sinus rhythm. Cochrane Database Syst Rev. 2014 Apr 28;4:CD002901.
  29. Lee AY, Kutyifa V, Ruwald MH, McNitt S, Polonsky B, Zareba W et al. Digoxin therapy and associated clinical outcomes in the MADIT-CRT trial. Heart Rhythm. 2015 Sep;12(9):2010–7.
  30. Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM et al. Increased mortality among patients taking digoxin-analysis from the AFFIRM study. Eur Heart J. 2013 May;34 (20):1481–8.
  31. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, Cleland JG, Butler J, Epstein AE et al. Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J. 2013 May;34 (20):1489–97.
  32. Turakhia MP, Santangeli P, Winkelmayer WC, Xu X, Ullal AJ, Than CT et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014 Aug 19;64 (7):660–8.
  33. Shah M, Tsadok MA, Jackevicius CA, Essebag V, Behloudi H, Pilote L. Relation of digoxin use in atrial fibrillation and the risk of all-cause mortality in patients ≥65 years of age with versus with-out heart failure. Am J Cardiol. 2014 Aug 1;114 (3):401–6.
  34. Hallberg P, Lindbäck J, Lindahl B, Stenestrand U, Melhus H. Digoxin and mortality in atrial fibrillation: a prospective cohort study. Eur J Clin Pharmacol. 2007 Oct;63 (10):959–71.
  35. Freeman JV, Reynolds K, Fang M, Udaltsova N, Steimle A, Pomernacki NK et al. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study. Circ Arrhythm Electrophysiol. 2015 Feb;8 (1):49–58.
  36. Washam JB, Stevens SR , Lokhnygina Y, Halperin JL, Breithardt G, Singer DE et al. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Lancet. 2015 Jun 13;385 (9985):2363–70.
  37. Gjesdal K, Feyzi J, Olsson SB. Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data. Heart. 2008 Feb;94 (2):191–6.
  38. Chao TF, Liu CJ, Chen SJ, Wang KL, Lin YJ, Chang SL et al. Does digoxin increase the risk of ischemic stroke and mortality in atrial fibrillation? A nationwide population-based cohort study. Can J Cardiol. 2014 Oct;30 (10):1190–5.
  39. Friberg L, Hammar N, Rosenqvist M. Digoxin in atrial fibrillation: report from the Stockholm Cohort study of Atrial Fibrillation (SCAF). Heart. 2010 Feb;96 (4):275–80.
  40. Pastori D, Farcomeni A, Bucci T, Cangemi R , Ciacci P, Vicario T et al. Digoxin treatment is associated with increased total and cardiovascular mortality in anticoagulated patients with atrial fibrillation. Int J Cardiol. 2015 Feb 1;180:1–5.
  41. Rodríguez-Mañero M, Otero-Raviña F, García-Seara J, Zugaza-Gurruchaga L, Rodriguez-Garcia JM, Blanco-Rodriguez R et al. Outcomes of a contemporary sample of patients with atrial fibrillation taking digoxin: results from the AFBAR study. Rev Esp Cardiol (Engl Ed). 2014 Nov;67 (11):890–7.
  42. Mulder BA, Van Veldhuisen DJ, Crijns HJ, Tijssen JG, Hillege HL, Alings M et al. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. Heart Rhythm. 2014 Sep;11 (9):1543–50.
  43. Virgadamo S, Charnigo R , Darrat Y, Morales G, Elayi CS. Digoxin: A systematic review in atrial fibrillation, congestive heart failure and post myocardial infarction. World J Cardiol. 2015 Nov 26;7 (11):808–16.
  44. Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. Eur Heart J. 2015 Jul 21;36 (28):1831–8.
  45. Chen Y, Cai X, Huang W, Wu Y, Huang Y, Hu Y. Increased all-cause mortality associated with digoxin therapy in patients with atrial fibrillation: an updated meta-analysis. Medicine (Baltimore). 2015 Dec;94 (52):e2409.
  46. Bavishi C, Khan AR , Ather S. Digoxin in patients with atrial fibrillation and heart failure: a meta-analysis. Int J Cardiol. 2015 Jun 1;188:99–101.
  47. Ouyang AJ, Lv YN, Zhong HL, Wen JH, Wei XH, Peng HW et al. Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation. Am J Cardiol. 2015 Apr 1;115 (7):901–6.
  48. Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015 Aug 30;35:h4451.
  49. Garcia-Rubira JC, Calvo-Taracido M, Francisco-Aparicio F, Almendro-Delia M, Recio-Mayoral A, Reina Toral A et al. The previous use of digoxin does not worsen early outcome of acute coronary syndromes: an analysis of the ARIAM Registry. Intern Emerg Med. 2014 Oct;9 (7):759–65.
  50. Køber L, Torp-Pedersen C, Gadsbøll N, Hildebrandt P, Høilund-Carlsen PF. Is digoxin an independent risk factor for long-term mortality after acute myocardial infarction? Eur Heart J. 1994 Mar;15 (3):382–8.
  51. Reicher-Reiss H, Jonas M, Boyko V, Shotan A, Goldbourt U, Behar S. Are coronary patients at higher risk with digoxin therapy? An ongoing controversy. Int J Cardiol. 1999 Feb 28;68 (2):137–43.
  52. Mathur PN, Powles P, Pugsley SO, McEwan MP, Campbell EJ. Effect of digoxin on right ventricular function in severe chronic airflow obstruction: a controlled clinical trial. Ann Intern Med. 1981 Sep;95 (3):283–8.
  53. Rich S, Seidlitz M, Dodin E, Osimani D, Judd D, Genthner D et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest. 1998 Sep;114 (3):787–92.
  54. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015 Oct;46 (4):903–75.
  55. Litonjua MR , Penton S, Robinson C, Daubert GP. Digoxin: the monarch of cardiac toxicities. J Pharm Pract. 2005 Jun;18 (3):157–68.
  56. Preiss D, van Veldhuisen DJ, Sattar N, Krum H, Swedberg K, Shi H et al. Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Euro J Heart Fail. 2012 Aug;14 (8):909–15.
  57. Chirinos JA, Castrellon A, Zambrano JP, Jimenez JJ, Jy W, Horstman LL et al. Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation. Heart Rhythm. 2005 May;2 (5):525–9.
  58. Biggar RJ. Molecular pathways: digoxin use and estrogen-sensitive cancers – risks and possible therapeutic implications. Clin Cancer Res. 2012 Apr 15;18 (8):2133–7.
  59. Ahern TP, Lash TL, Sørensen HT, Pedersen L. Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study. Breast Cancer Res. 2008;10 (6):R102.
  60. Biggar RJ, Wohlfahrt J, Melbye M. Digoxin use and the risk of cancers of the corpus uteri, ovary and cervix. Int J Cancer. 2012 Aug 1;131 (3):716–21.
  61. Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A. Risk factors for male breast cancer – a case-control study from Scandinavia. Acta Oncol. 2001;40 (4):467–71.
  62. Platz EA, Yegnasubramanian S, Liu JO, Chong CR , Shim JS, Kenfield SA et al. A novel two-stage transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov. 2011 Jun;1 (1):68–77.
  63. Newman RA, Yang P, Pawlus AD, Block KI. Cardiac glycosides as novel cancer therapeutic agents. Mol Interv. 2008 Feb;8 (1):36–49.
  64. Elbaz HA, Stueckle TA, Tse W, Rojanasakul Y, Dinu CZ. Digitoxin and its analogs as novel cancer therapeutics. Exp Hematol Oncol. 2012 Apr 5;1 (1):4.
  65. Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. J Am Soc Nephrol. 2010 Sep;21 (9):1550–9.
  66. Cleland JG, Cullington D. Digoxin quo vadis? Circ Heart Fail. 2009 Mar;2 (2):81–5.
  67. Арутюнов А.Г., Рылова А.К., Арутюнов Г.П. Регистр госпитализированных пациентов с декомпенсацией кровообращения (Павловский регистр). Сообщение 1. Современная клиническая характеристика пациента с декомпенсацией кровообращения. Клинические фенотипы пациентов. Журнал Сердечная Недостаточность. 2014;15 (1):23–32 [Arutyunov A.G., Ry`lova A.K., Arutyunov G.P. Registr gospitalizirovanny`x paczientov s dekompensacziej krovoobrashheniya (Pavlovskij registr). Soobshhenie 1. Sovremennaya klinicheskaya xarakteristika paczienta s dekompensacziej krovoobrashheniya. Klinicheskie fenotipy` paczientov. Zhurnal Serdechnaya Nedostatochnost`. 2014;15 (1):23–32].
  68. Ситникова М.Ю., Лясникова Е.А., Юрченко А.В., Трукшина М.А., Либис Р.А., Кондратенко В.Ю. и др. Результаты Российского госпитального регистра хронической сердечной недостаточности в 3 субъектах Российской Федерации. Кардиология. 2015;55 (10):5–13 [Sitnikova M.Yu., Lyasnikova E.A., Yurchenko A.V., Trukshina M.A., Libis R.A., Kondratenko V.Yu. i dr. Rezul`taty` Rossijskogo gospital`nogo registra xronicheskoj serdechnoj nedostatochnosti v 3 sub``ektax Rossijskoj Federaczii. Kardiologiya. 2015;55 (10):5–13].
Lyasnikova E.A., Sitnikova M.Yu. Controversial questions of pharmacotherapy of chronic heart failure (Review). Part 1. Kind/evil magician digoxin. Russian Heart Failure Journal. 2016;17 (6):388–397

To access this material please log in or register

Register Authorize
Ru En